Artificial pancreas to undergo long-term clinical tests

January 4, 2016
Picture of an artificial pancreas. Credit: Peter Allen, Harvard Paulson School of Engineering and Applied Sciences

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad.

With $12.7 million in support from the National Institutes of Health (NIH), the system developed by a team of researchers from the University of Virginia (UVA) School of Medicine and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) will be tested in 240 patients at nine sites in the U.S. and Europe. The two six-month trials will begin in early 2016, in collaboration with a half dozen other institutional partners.

Already one of the most common chronic disorders, the incidence of diabetes is increasing worldwide. According to the U.S. Centers for Disease Control and Prevention, 1.25 million Americans have type 1 diabetes. In people living with the disease, the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas so that little or none of the insulin needed to regulate blood glucose is produced. Diabetics must vigilantly monitor blood glucose levels and, when necessary, administer doses of insulin either via needle injections or infusion pump. Failure to maintain proper blood glucose levels through insulin management can cause life-threatening hyperglycemia, or , among other complications.

"To be ultimately successful as an optimal treatment for diabetes, the needs to prove its safety and efficacy in long-term pivotal trials in the patient's natural environment," said principle investigator Boris Kovatchev, director of the UVA Center for Diabetes Technology. "Our foremost goal is to establish a new diabetes treatment paradigm: the artificial pancreas is not a single-function device; it is an adaptable, wearable network surrounding the patient in a digital treatment ecosystem."

The video will load shortly

Through a marriage of control engineering with medical practice and behavioral science, the artificial pancreas system is designed to supply the appropriate levels of insulin by not only reacting to changes in the body, but accurately predicting in advance.

The artificial pancreas is not a replica organ; it is an automated insulin delivery system designed to mimic a healthy person's glucose regulating function. The closed-loop system consists of an insulin pump, continuous glucose monitor placed under the user's skin, and advanced control algorithm software embedded in a smart phone that provides the engineering brains, signaling how much insulin the pump should deliver to the patient based on a range of variables including meals consumed, physical activity, sleep, stress, and metabolism.

Pioneering artificial pancreas to undergo final tests
An example of a user interface of the artificial pancreas. Credit: UVA Health

"The idea is that this can lead to an improved quality of life for individuals with this disease—not a solution to diabetes, but a means to really extend the quality of their healthful living," said co-principal investigator and engineering lead on the project Francis J. Doyle III, dean and John A. & Elizabeth S. Armstrong Professor of Engineering & Applied Sciences at Harvard SEAS.

In the first of the two trials planned as part of the new NIH-funded study, 240 patients with type 1 diabetes will test the safety and effectiveness of the artificial pancreas for six months while going about their normal daily routines. The control-to-range artificial pancreas system for this trial was developed at UVA and is now licensed to TypeZero Technologies. The artificial pancreas will be compared with a standard insulin pump on two key measures: how well are controlled and whether the risk of hypoglycemia is reduced.

The second trial will follow 180 patients who completed the first study for an additional six months to test the advanced adaptive control algorithm developed by Doyle's Harvard team. That system is based on zone model-predictive control (zone MPC), a strategy originally developed by Doyle and colleagues in a seminal paper published in 1996. Rather than regulating glucose levels to a specific point in the same way that a home thermostat keeps the room temperature at a precise setting, zone-MPC defines an acceptable zone for an individual's and controls variables to stay within that range.

"The biggest challenge in the design of the artificial pancreas is the inherent uncertainty in the human body," Doyle noted. "Day to day, hour to hour, the various stresses that impact the human body change the way it responds to insulin-controlling glucose. Physical stresses, anxiety, hormonal swings will all change that balance. To be able to control for those factors we need to see longer intervals of data. This is the first trial where we'll be looking at multi-month intervals of time with cohorts of subjects where we can actually see a long enough window to learn those patterns, to adapt and fine-tune the algorithms, and to improve the overall level of glucose control."

Explore further: Dual-hormone artificial pancreas is a step closer for patients with Type 1 diabetes

Related Stories

Artificial pancreas works well in home trial

September 17, 2015

(HealthDay)—The latest trial of an artificial pancreas system offers good news for people with type 1 diabetes—the system lowered blood sugar levels without increasing the risk of dangerously low blood sugar (hypoglycemia), ...

Artificial pancreas therapy performs well in pilot study

November 20, 2015

Researchers are reporting a breakthrough toward developing an artificial pancreas as a treatment for diabetes and other conditions by combining mechanical artificial pancreas technology with transplantation of islet cells, ...

Recommended for you

Do germs cause type 1 diabetes?

May 16, 2016

Germs could play a role in the development of type 1 diabetes by triggering the body's immune system to destroy the cells that produce insulin, new research suggests.

Melatonin signaling is a risk factor for type 2 diabetes

May 12, 2016

A sleeping pancreas releases less insulin, but how much insulin drops each night may differ from person to person, suggests a study published May 12, 2016 in Cell Metabolism. Up to 30 percent of the population may be predisposed ...

New gene for familial high cholesterol

May 12, 2016

New research from Denmark reveals the gene that explains one quarter of all familial hypercholesterolemia with very high blood cholesterol. Familial hypercholesterolemia is the most common genetic disorder leading to premature ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

sagittarius420itstrue
5 / 5 (1) Jan 04, 2016
Your advice will kill a type 1 diabetic. Type 1 and 2 are completely different diseases! Please educate yourself before making recommendations. Thank you
erikawolford
not rated yet Jan 05, 2016
mgdanimals4 - I appreciate the fact that you're trying to help people, but your advice has no place in these comments, as we're commenting on an article about Type 1 Diabetes, not Type 2. You might as well be giving out recommendations about IBS or a broken bone.

That being said, this is very exciting new for those of us with Type 1 Diabetes. Thank you to all of the researchers and volunteers!
RealScience
not rated yet Jan 11, 2016
@sagittarius and erika - mgdanimals4 has copied the same promotion for the Sidorov book into numerous threads that mention 'diabetes' - that's just spam.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.